Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RIGL Stock Forecast 2025-2026
$18.77
Current Price
$335.46M
Market Cap
Buy 2
Hold 4
Sell 0
Wall St Analyst Ratings
Distance to RIGL Price Targets
+203.7%
To High Target of $57.00
+25.2%
To Median Target of $23.50
+9.0%
To Low Target of $20.45
RIGL Price Momentum
-1.8%
1 Week Change
+12.5%
1 Month Change
+91.5%
1 Year Change
+11.6%
Year-to-Date Change
-37.1%
From 52W High of $29.82
+150.9%
From 52W Low of $7.48
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Rigel (RIGL) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on RIGL and similar high-potential opportunities.
Latest RIGL Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, RIGL has a neutral consensus with a median price target of $23.50 (ranging from $20.45 to $57.00). The overall analyst rating is Buy (7.0/10). Currently trading at $18.77, the median forecast implies a 25.2% upside. This outlook is supported by 2 Buy, 4 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Joseph Pantginis at HC Wainwright & Co., projecting a 203.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RIGL Analyst Ratings
2
Buy
4
Hold
0
Sell
RIGL Price Target Range
Low
$20.45
Average
$23.50
High
$57.00
Current: $18.77
Latest RIGL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RIGL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 7, 2025 | Cantor Fitzgerald | Kristen Kluska | Neutral | Maintains | $23.00 |
| Mar 6, 2025 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $55.00 |
| Mar 5, 2025 | B. Riley Securities | Kalpit Patel | Neutral | Maintains | $24.00 |
| Mar 5, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $57.00 |
| Jan 23, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $57.00 |
| Jan 22, 2025 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| Jan 14, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $57.00 |
| Dec 10, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $57.00 |
| Dec 10, 2024 | Cantor Fitzgerald | Kristen Kluska | Neutral | Maintains | $25.00 |
| Dec 10, 2024 | B. Riley Securities | Kalpit Patel | Neutral | Maintains | $20.00 |
| Dec 6, 2024 | B. Riley Securities | Kalpit Patel | Neutral | Maintains | $27.00 |
| Nov 14, 2024 | Piper Sandler | Allison Bratzel | Neutral | Maintains | $23.00 |
| Nov 12, 2024 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $49.00 |
| Oct 25, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $57.00 |
| Sep 20, 2024 | Cantor Fitzgerald | Kristen Kluska | Neutral | Reiterates | $15.00 |
| Sep 5, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $57.00 |
| Sep 3, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $57.00 |
| Aug 9, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $57.00 |
| Jun 25, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $15.00 |
| Jun 17, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $15.00 |
Rigel Pharmaceuticals Inc. (RIGL) Competitors
The following stocks are similar to Rigel based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Rigel Pharmaceuticals Inc. (RIGL) Financial Data
Rigel Pharmaceuticals Inc. has a market capitalization of $335.46M with a P/E ratio of 9.0x. The company generates $203.08M in trailing twelve-month revenue with a 18.3% profit margin.
Revenue growth is +80.6% quarter-over-quarter, while maintaining an operating margin of +24.0% and return on equity of +531.8%.
Valuation Metrics
Market Cap
$335.46M
Enterprise Value
$359.41M
P/E Ratio
9.0x
PEG Ratio
21.3x
Price/Sales
1.7x
Growth & Margins
Revenue Growth (YoY)
+80.6%
Gross Margin
+91.7%
Operating Margin
+24.0%
Net Margin
+18.3%
EPS Growth
+80.6%
Financial Health
Cash/Price Ratio
+23.0%
Current Ratio
2.2x
Debt/Equity
544.2x
ROE
+531.8%
ROA
+18.2%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Rigel Pharmaceuticals Inc. (RIGL) Business Model
About Rigel Pharmaceuticals Inc.
What They Do
Biotechnology company developing small molecule drugs.
Business Model
Rigel Pharmaceuticals operates by discovering and developing small molecule drugs aimed at treating inflammatory, autoimmune diseases, and cancer-related disorders. The company generates revenue through the advancement of its therapeutic candidates via research and clinical trials, often collaborating with various clinical and research partners to bring new therapies to market.
Additional Information
Headquartered in San Francisco, Rigel is focused on addressing unmet medical needs and enhancing patient health outcomes. Its proprietary technology platform is key to identifying and optimizing drug candidates that target specific intracellular signaling pathways.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
162
CEO
Mr. Raul R. Rodriguez
Country
United States
IPO Year
2000
Website
www.rigel.comRigel Pharmaceuticals Inc. (RIGL) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Earnings Estimates Rising for Rigel (RIGL): Will It Gain?
Rigel (RIGL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
May 09, 2025
By Zacks Equity Research
Tale of the Tape
Rigel Pharmaceuticals (RIGL) Beats Q1 Earnings and Revenue Estimates
Rigel (RIGL) delivered earnings and revenue surprises of 350% and 22.07%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
May 06, 2025
By Zacks Equity Research
Tale of the Tape
Ardelyx (ARDX) Reports Q1 Loss, Misses Revenue Estimates
Ardelyx (ARDX) delivered earnings and revenue surprises of -70% and 8.14%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
May 01, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Rigel (RIGL) shares are rising, supported by positive earnings estimate revisions, suggesting potential for continued upward momentum.
Why It Matters
RIGL's rising share price and positive earnings estimate revisions signal potential growth and increased investor confidence, suggesting possible future gains.
Source: Zacks Investment Research
Market Sentiment:
Positive
Wall Street Analysts Think Rigel (RIGL) Could Surge 82.3%: Read This Before Placing a Bet
4 days ago
Quick Summary
Analysts' price targets for Rigel (RIGL) suggest an 82.3% upside, supported by a consensus in raised earnings estimates, indicating potential positive movement in the stock.
Why It Matters
Analysts' consensus on Rigel's price target suggests significant potential for growth, indicating bullish sentiment that may attract investor interest and drive stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Rigel Pharmaceuticals will hold its Q1 2025 earnings conference call on May 6, 2025, at 4:30 PM ET, featuring key executives including the CEO and CFO.
Why It Matters
The earnings call will provide insights into Rigel Pharmaceuticals' financial performance and strategic direction, affecting stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Rigel Pharmaceuticals reported a 68% YoY revenue increase, with Q1 net income of $11.4M. TAVALISSE's patent extends to 2032, supporting growth and reducing fundraising needs.
Why It Matters
Rigel's 68% YoY revenue growth and improved margins signal strong business health, reducing dilution risks and enhancing R&D capabilities, which could attract long-term investment interest.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
In Q1 2025, the company reported total revenue of $53.3 million, with net income of $11.4 million. It received FDA designations for R289. 2025 revenue outlook is $200-$210 million.
Why It Matters
Strong revenue growth and profitability signal positive business momentum. FDA designations enhance R289's market potential, boosting future sales prospects and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Rigel Pharmaceuticals (RIGL) reported Q3 earnings of $0.63 per share, exceeding the Zacks estimate of $0.14, compared to a loss of $0.50 per share the previous year.
Why It Matters
Rigel Pharmaceuticals' strong earnings beat expectations and show a significant turnaround from a loss last year, indicating improved financial health and potential growth, attracting investor interest.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About RIGL Stock
What is Rigel Pharmaceuticals Inc.'s (RIGL) stock forecast for 2025?
Based on our analysis of 8 Wall Street analysts, Rigel Pharmaceuticals Inc. (RIGL) has a median price target of $23.50. The highest price target is $57.00 and the lowest is $20.45.
Is RIGL stock a good investment in 2025?
According to current analyst ratings, RIGL has 2 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $18.77. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RIGL stock?
Wall Street analysts predict RIGL stock could reach $23.50 in the next 12 months. This represents a 25.2% increase from the current price of $18.77. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Rigel Pharmaceuticals Inc.'s business model?
Rigel Pharmaceuticals operates by discovering and developing small molecule drugs aimed at treating inflammatory, autoimmune diseases, and cancer-related disorders. The company generates revenue through the advancement of its therapeutic candidates via research and clinical trials, often collaborating with various clinical and research partners to bring new therapies to market.
What is the highest forecasted price for RIGL Rigel Pharmaceuticals Inc.?
The highest price target for RIGL is $57.00 from Joseph Pantginis at HC Wainwright & Co., which represents a 203.7% increase from the current price of $18.77.
What is the lowest forecasted price for RIGL Rigel Pharmaceuticals Inc.?
The lowest price target for RIGL is $20.45 from at , which represents a 9.0% increase from the current price of $18.77.
What is the overall RIGL consensus from analysts for Rigel Pharmaceuticals Inc.?
The overall analyst consensus for RIGL is neutral. Out of 8 Wall Street analysts, 2 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $23.50.
How accurate are RIGL stock price projections?
Stock price projections, including those for Rigel Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 12, 2025 12:13 PM UTC